Pregnant women in Australia are facing a two-tiered system for managing morning sickness, with financial status affecting access to modern anti-nausea medications rather than clinical need, according to an Aug. 5 study led by the University of Technology Sydney.
The research found that Australia's Pharmaceutical Benefits Scheme (PBS) is not meeting the therapeutic needs of pregnant patients, resulting in widespread off-label prescribing and reinforcing structural health inequities. Nausea and vomiting in pregnancy affects up to 80 percent of pregnant women, but only 10 to 20 percent use conventional medications.
Lead author Dr. Hannah Jackson from the UTS Faculty of Health said treatment has a complex history due to the thalidomide tragedy, leading to conservative pharmaceutical regulations and limited innovation. The study analyzed PBS dispensing records from nearly 300,000 pregnancies over five years to examine how public resources for anti-nausea medications were distributed across socioeconomic regions.
"We found that in some cases prescribers were finding alternative ways to get women the medication they need in a community-based setting, which can reduce health system costs by keeping them out of hospital," Jackson said. The findings show that while the PBS provides affordable access to necessary medications, its narrow range of approved drugs for pregnancy-related nausea can create significant disparities in treatment type and cost.
Ondansetron accounted for 54 percent of total PBS expenditure on anti-nausea medications during pregnancy despite lacking official approval or specific listing under the PBS framework. "Because official subsidised options are so limited, doctors frequently rely on system workarounds to ensure patients on low incomes can afford necessary treatment," Jackson said. Total PBS-funded expenditure was concentrated among disadvantaged women, with ondansetron use rising faster in low-income areas.
Associate Professor Luke Grzeskowiak from Flinders University said, "the observed system workarounds create a kind of 'Robin Hood' scenario, where providing medicines outside of PBS restrictions is seen as an acceptable workaround because it's helping vulnerable women get necessary treatment they would otherwise not be able to afford." Grzeskowiak also said that with fewer subsidised medications available through the PBS, pregnant women with lower financial capacity must rely on older therapies while those with more means pay out-of-pocket for non-PBS options which may be more suitable.
The authors argue that limited access through the PBS drives inequalities by seeing disadvantaged women access only subsidised medications while affluent women self-fund other recommended treatments. With maternal health designated as a national priority, researchers urge policymakers to expand funding structures and approve more pregnancy-relevant medications under the PBS framework. "Without reform, the current policy framework will continue to perpetuate socioeconomic inequalities, incentivise prescribing outside of standard regulatory safeguards, and lead to potential inefficiencies in public spending," Jackson said.
